How to evaluate a stem cell clinic claim before paying for treatment

Before you pay for anything marketed as a stem cell treatment, get four things in writing: exactly what preparation will be injected, what evidence supports it for your diagnosis and stage, what the plan is if it does not work, and what baseline data was required before the plan was made. If a clinic cannot supply those four, you do not have enough information to consent, regardless of how the treatment is described.

This matters because the concern is documented in the orthopaedic literature. A 2020 annotation in The Bone & Joint Journal describes growing concern about an increasing number of clinical centers worldwide making unwarranted claims or performing risky biological procedures, and notes that such providers have been known to recommend, prescribe, or deliver so-called stem cell preparations without sufficient data to support their true content and efficacy.

The seven-point checklist

1. Name the product. Which specific preparation, from which of your tissues, processed how?
2. Match the claim to your diagnosis. Is the evidence for your condition at your stage, or for a related condition in a different population?
3. Ask what oversight applies. What regulatory pathway, if any, applies to this specific product for this specific indication?
4. Get the plan in writing. What is tried first, what would change it, and what would stop it?
5. Require baseline data first. What labs, imaging, and history are needed before a procedure is proposed, not after you have paid?
6. Insist on conservative-first logic. What non-procedural measures come before this, and have they been tried?
7. Get a second opinion that can explain itself. A useful second opinion names its reasoning, not just its conclusion.

Start with the product, not the word “stem cells”

“Stem cells” functions as a marketing umbrella. Your decision has to be anchored to what will physically be administered to you, which means translating the brochure language into checkable specifics.

Ask for plain written answers to four questions. What exact cell type or preparation is used? What processing steps are performed on it? What testing is done on the final preparation, and can the results be shared? What anatomical target is being treated, and how is it reached?

If a clinic will not describe the preparation clearly, or will not document what was tested, that is the answer. The absence of a specific description is itself the finding.

Match the claim to your diagnosis and your stage

Supportive data for a related condition does not transfer automatically to yours. A clinic should be able to connect the evidence it cites to your specific diagnosis, your imaging findings, and your disease stage — and to say plainly when that connection is weak.

For joint problems, ask whether the stated goal is symptom control, function, or a bridge while other measures continue. Those are three different promises, and only the honest ones distinguish between them.

Be particularly careful with cartilage claims. No orthobiologic has been shown to regrow or regenerate articular cartilage. For advanced knee osteoarthritis, platelet-rich plasma is appropriately described the way trial authors describe it — a bridge therapy prior to joint replacement — and a clinic promising structural repair has left the evidence behind.

Separate “promising” from “proven”

Ask which type of evidence the clinic is relying on: peer-reviewed clinical trials, or internal case series and testimonials. Then ask how the outcomes were measured and over what period.

Four gaps come up repeatedly. Outcome mismatch: improvement is claimed without specifying what was measured or how often. Population mismatch: evidence from one subgroup is applied to a different stage of disease or a different comorbidity profile. Mechanism overreach: marketing implies a biological process the trial authors never demonstrated. Unclear reporting: study details, measurement methods, and limitations are not available on request.

Any one of those is a reason to slow down. All four together describe a sales process, not a clinical one.

Ask about the preparation and its processing

Due diligence on an autologous preparation focuses on how it is made. Ask whether it is prepared from your own tissue, how it is collected, and how it is handled between collection and injection.

Specific versions of that question, depending on what you are being offered: for bone marrow aspirate concentrate, how is the aspirate concentrated and what documents the final content? For micro-fragmented adipose, how is the fat processed? For intraosseous or subchondral PRP, what is the injection target and what imaging guidance is used to reach it? For PRP generally, what preparation method is used?

Clinics vary widely in how they answer. A clinic that gives you a consistent description of both the product and the plan is one you can actually evaluate; one that does not is one you cannot. How Regen.MD describes each of these categories is set out on our orthobiologics service page.

Ask about oversight and how carefully claims are worded

Regulatory status does not prove a treatment works, but it does test whether a clinic’s claims are consistent with its oversight. Ask what regulatory pathway, if any, applies to the specific product for the specific indication being offered.

Then ask for four things in writing: clear documentation of the specific product rather than a procedure name; transparent reporting on what tests verify its content; how safety monitoring and adverse event reporting are handled; and a written summary of how the clinic’s claim aligns with published evidence for your condition.

Vague assurances in place of documentation are a reason to pause. At Regen.MD, that documentation is assembled as part of the evaluation rather than afterward; the sequence is described in our evaluation pathway.

Look for a written pathway, not a one-visit pitch

Even a clinic offering legitimate orthobiologics should be able to hand you a sequence of decisions rather than a single procedure. Ask for a written plan covering the baseline data required before any procedure is proposed, the intervention sequence and what is attempted first, the outcomes that would guide continuing, adjusting, or stopping, and how escalation is avoided in the absence of documentation.

This matters most in exactly the situations where patients feel most urgent. If you have been told to avoid knee replacement without a written pathway and without measurable monitoring, you have been given a slogan rather than a plan.

Apply the same scrutiny to bundled offerings

Cell therapy marketing is often packaged alongside peptide and longevity programs. The due diligence does not change: clear documentation, defined monitoring, and alignment between what is claimed and what is supported.

Confusion arises when separate services are presented as one treatment package. Ask for each component to be justified and monitored on its own terms. At Regen.MD, peptides are discussed as a clinical and educational subject and are not sold as a product.

Frequently asked questions

Sources

1. Murray IR, Chahla J, Frank RM, Piuzzi NS, Mandelbaum BR, Dragoo JL; Members of the Biologics Association. Rogue stem cell clinics. The Bone & Joint Journal. 2020;102-B(2):148–154. https://pubmed.ncbi.nlm.nih.gov/32009438/ (Referenced for: growing concern about an increasing number of clinical centers making unwarranted claims or performing risky biological procedures, and providers recommending, prescribing, or delivering so-called stem cell preparations without sufficient data to support their true content and efficacy.)